Non-Hodgkin Lymphoma

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Marcel R.M. van den Brink, MD, PhD, Head, discusses a trial being presented at the 2013 ASH Annual Meeting, analyzing the addition of ibrutinib to R-CHOP in patients with non-Hodgkin's lymphoma (NHL).

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.

Adding ibrutinib to standard R-CHOP chemotherapy for non-Hodgkin lymphoma resulted in an objective response rate of 100% in the first-line setting.

A dual-target PI3 kinase inhibitor known as IPI-145 demonstrated activity in several types of relapsed and refractory non-Hodgkin lymphoma.

A late-stage trial investigating inotuzumab ozogamicin as a treatment for patients with aggressive non-Hodgkin lymphoma has been halted after interim data showed the agent was unlikely to improve survival.

Routine follow-up imaging is of limited value in determining whether patients with diffuse large B-cell lymphoma have experienced a relapse of their disease.

Follicular lymphoma is characterized by repeated treatment responses and then relapses, and until more effective frontline therapies become available, researchers will need to generate a growing list of drug choices to keep pace with patients' needs.

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, discusses the diagnosis of patients with follicular lymphoma.

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses MALT1 as a potential target for patients with activated B cell-like diffuse large B-cell lymphoma.

Andrew D. Zelenetz, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Treatment Options for DLBCL

The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses Treatment Options for Primary Mediastinal B Cell Lymphoma

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Newly-diagnosed asymptomatic follicular lymphoma patients with low tumor burden can have their initial treatment delayed.